Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Journal of Autism and Developmental Disorders
|
March 18, 2023
Resting-State Activity in Children: Replicating and Extending Findings of Early Maturation of Alpha Rhythms in Autism Spectrum Disorder
Guannan Shen, Heather L Green, Rose E Franzen, et al.
The Lancet. Oncology
|
July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Ejhaem
|
April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Briony Shaw, Eliza Chung, Cameron Wellard, et al.
Journal of Autism and Developmental Disorders
|
August 12, 2022
Differential Maturation of Auditory Cortex Activity in Young Children with Autism and Typical Development
Heather L Green, Guannan Shen, Rose E Franzen, et al.
Frontiers in Human Neuroscience
|
March 14, 2014
Artemis 123: development of a whole-head infant and young child MEG system
Timothy P L Roberts, Douglas N Paulson, Eugene Hirschkoff, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
Adrian Minson, Emma Verner, Pratyush Giri, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2022
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S Nowakowski, Dok Hyun Yoon, Anthea Peters, et al.
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Journal of Autism and Developmental Disorders
|
March 18, 2023
Resting-State Activity in Children: Replicating and Extending Findings of Early Maturation of Alpha Rhythms in Autism Spectrum Disorder
Guannan Shen, Heather L Green, Rose E Franzen, et al.
The Lancet. Oncology
|
July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Ejhaem
|
April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Briony Shaw, Eliza Chung, Cameron Wellard, et al.
Journal of Autism and Developmental Disorders
|
August 12, 2022
Differential Maturation of Auditory Cortex Activity in Young Children with Autism and Typical Development
Heather L Green, Guannan Shen, Rose E Franzen, et al.
Frontiers in Human Neuroscience
|
March 14, 2014
Artemis 123: development of a whole-head infant and young child MEG system
Timothy P L Roberts, Douglas N Paulson, Eugene Hirschkoff, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
Adrian Minson, Emma Verner, Pratyush Giri, et al.
Page
of 7